Table 3. Distribution of baseline and probe trials with failures to respond during the first equivalence block.

Subject	Trials	Baseline	Probe	Two consecutive
ALE	1–36	1	4	0
	37–72	3	5	0
	73–108	1	0	0
	109–144	0	4	1
CA	1–36	1	3	1
	37–72	0	0	0
	73–108	0	6	0
	109–144	1	2	1
EMM	1–36	2	6	2
	37–72	0	2	0
	73–108	0	1	0
	109–144	1	1	0
PLRA	1–36	2	7	1
	37–72	3	4	1
	73–108	0	8	2
	109–144	1	5	0
SU	1–36	1	2	0
	37–72	2	2	0
	73–108	2	1	1
	109–144	0	0	0

Note: “Two Consecutive” indicates the number of times the subject failed to respond for two consecutive trials.